OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine

We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA (BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP MAbs) in treatment-refractory patients with chronic migraine (CM). We retrospectively reviewed the medical files of 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Argyriou, Andreas A., Dermitzakis, Emmanouil V., Xiromerisiou, Georgia, Vikelis, Michail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785576/
https://www.ncbi.nlm.nih.gov/pubmed/36548744
http://dx.doi.org/10.3390/toxins14120847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785576/
https://www.ncbi.nlm.nih.gov/pubmed/36548744
http://dx.doi.org/10.3390/toxins14120847

Ejemplares similares